BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26397192)

  • 1. Overexpression of osteopontin promotes resistance to cisplatin treatment in HCC.
    Ding K; Fan L; Chen S; Wang Y; Yu H; Sun Y; Yu J; Wang L; Liu X; Liu Y
    Oncol Rep; 2015 Dec; 34(6):3297-303. PubMed ID: 26397192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteopontin induces autophagy to promote chemo-resistance in human hepatocellular carcinoma cells.
    Liu G; Fan X; Tang M; Chen R; Wang H; Jia R; Zhou X; Jing W; Wang H; Yang Y; Yin F; Wei H; Li B; Zhao J
    Cancer Lett; 2016 Dec; 383(2):171-182. PubMed ID: 27702661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway.
    Cao L; Fan X; Jing W; Liang Y; Chen R; Liu Y; Zhu M; Jia R; Wang H; Zhang X; Zhang Y; Zhou X; Zhao J; Guo Y
    Oncotarget; 2015 Mar; 6(9):6627-40. PubMed ID: 25749383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation and prognostic value of osteopontin and Bcl-2 in hepatocellular carcinoma patients after curative resection.
    Deng B; Zhang XF; Zhu XC; Huang H; Jia HL; Ye QH; Dong QZ; Qin LX
    Oncol Rep; 2013 Dec; 30(6):2795-803. PubMed ID: 24065086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-C chemokine receptor type 1 mediates osteopontin-promoted metastasis in hepatocellular carcinoma.
    Zhu Y; Gao XM; Yang J; Xu D; Zhang Y; Lu M; Zhang Z; Sheng YY; Li JH; Yu XX; Zheng Y; Dong QZ; Qin LX
    Cancer Sci; 2018 Mar; 109(3):710-723. PubMed ID: 29285854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of CD29-ILK-Akt signaling-mediated epithelial-mesenchymal transition of liver epithelial cells and chemoresistance and radioresistance in hepatocellular carcinoma cells.
    Jiang X; Wang J; Zhang K; Tang S; Ren C; Chen Y
    Med Oncol; 2015 May; 32(5):141. PubMed ID: 25805567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteopontin promotes hepatocellular carcinoma invasion by up-regulating MMP-2 and uPA expression.
    Chen RX; Xia YH; Xue TC; Ye SL
    Mol Biol Rep; 2011 Aug; 38(6):3671-7. PubMed ID: 21104439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA.
    Chen RX; Xia YH; Xue TC; Zhang H; Ye SL
    Oncol Rep; 2011 Mar; 25(3):803-8. PubMed ID: 21174062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transactivation of human osteopontin promoter by human T-cell leukemia virus type 1-encoded Tax protein.
    Zhang J; Yamada O; Matsushita Y; Chagan-Yasutan H; Hattori T
    Leuk Res; 2010 Jun; 34(6):763-8. PubMed ID: 19767100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Luteolin induces caspase-dependent apoptosis via inhibiting the AKT/osteopontin pathway in human hepatocellular carcinoma SK-Hep-1 cells.
    Im E; Yeo C; Lee EO
    Life Sci; 2018 Sep; 209():259-266. PubMed ID: 30107166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thirty-kilodalton Tat-interacting protein suppresses tumor metastasis by inhibition of osteopontin transcription in human hepatocellular carcinoma.
    Zhao J; Lu B; Xu H; Tong X; Wu G; Zhang X; Liang A; Cong W; Dai J; Wang H; Wu M; Guo Y
    Hepatology; 2008 Jul; 48(1):265-75. PubMed ID: 18537194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Segment-specific targeting via RNA interference mediates down-regulation of OPN expression in hepatocellular carcinoma cells.
    Lin F; Huang CM; Cao J; Pei ZH; Gu WL; Fan SF; Li KP; Lin CM
    Genet Mol Res; 2015 Nov; 14(4):14440-7. PubMed ID: 26600502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interference of osteopontin expression inhibits the invasion and metastasis of human hepatocellular carcinoma cell lines].
    Lin F; Li YY; Xia JT; Wen MJ; Lai YY; Cai WS; Wu ZF; Fan SF
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):422-5. PubMed ID: 19567019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer.
    Gu T; Ohashi R; Cui R; Tajima K; Yoshioka M; Iwakami S; Sasaki S; Shinohara A; Matsukawa T; Kobayashi J; Inaba Y; Takahashi K
    Lung Cancer; 2009 Nov; 66(2):176-83. PubMed ID: 19285749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spatial localization of the JAG1/Notch1/osteopontin cascade modulates extrahepatic metastasis in hepatocellular carcinoma.
    Xue TC; Zou JH; Chen RX; Cui JF; Tang ZY; Ye SL
    Int J Oncol; 2014 Nov; 45(5):1883-90. PubMed ID: 25176314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1.
    Qin J; Luo M; Qian H; Chen W
    Gene; 2014 Apr; 538(2):342-7. PubMed ID: 24447717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma.
    Pan HW; Ou YH; Peng SY; Liu SH; Lai PL; Lee PH; Sheu JC; Chen CL; Hsu HC
    Cancer; 2003 Jul; 98(1):119-27. PubMed ID: 12833464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LIFR functions as a metastasis suppressor in hepatocellular carcinoma by negatively regulating phosphoinositide 3-kinase/AKT pathway.
    Luo Q; Wang C; Jin G; Gu D; Wang N; Song J; Jin H; Hu F; Zhang Y; Ge T; Huo X; Chu W; Shu H; Fang J; Yao M; Gu J; Cong W; Qin W
    Carcinogenesis; 2015 Oct; 36(10):1201-12. PubMed ID: 26249360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcription factor c-Myb promotes the invasion of hepatocellular carcinoma cells via increasing osteopontin expression.
    Chen RX; Xia YH; Xue TC; Ye SL
    J Exp Clin Cancer Res; 2010 Dec; 29(1):172. PubMed ID: 21190594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hexabromocyclododecane and polychlorinated biphenyls increase resistance of hepatocellular carcinoma cells to cisplatin through the phosphatidylinositol 3-kinase/protein kinase B pathway.
    An J; Wang X; Guo P; Zhong Y; Zhang X; Yu Z
    Toxicol Lett; 2014 Aug; 229(1):265-72. PubMed ID: 24960055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.